Full Text
The Full Text of this article is available as a PDF (48.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Garfein R. S., Vlahov D., Galai N., Doherty M. C., Nelson K. E. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996 May;86(5):655–661. doi: 10.2105/ajph.86.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hagan H., Jarlais D. C., Friedman S. R., Purchase D., Alter M. J. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995 Nov;85(11):1531–1537. doi: 10.2105/ajph.85.11.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hunter G. M., Donoghoe M. C., Stimson G. V., Rhodes T., Chalmers C. P. Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993. AIDS. 1995 May;9(5):493–501. [PubMed] [Google Scholar]
- Robertson J. R., Ronald P. J., Raab G. M., Ross A. J., Parpia T. Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years. BMJ. 1994 Aug 6;309(6951):369–372. doi: 10.1136/bmj.309.6951.369. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wodak A., Crofts N. Once more unto the breach: controlling hepatitis C in injecting drug users. Addiction. 1996 Feb;91(2):181–184. doi: 10.1111/j.1360-0443.1996.tb03174.x. [DOI] [PubMed] [Google Scholar]